2024-12-17 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Divergence:**

Merck & Co Inc (MRK) is a leading pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare products.

The cumulative return of MRK (64.42%) significantly underperformed the S&P 500 (VOO) (121.78%) over the analyzed period.  The final divergence is -57.4%, meaning MRK underperformed VOO by 57.4 percentage points.  The relative divergence of -5.6% places it in the lower range of its historical performance relative to the S&P 500 based on the provided min/max range.  The provided alpha consistently shows negative values, further indicating underperformance relative to the market benchmark.


**2. Recent Price Movement:**

* **Closing Price:** $100.06
* **5-day Moving Average:** $100.81
* **20-day Moving Average:** $100.77
* **60-day Moving Average:** $104.86

The current price is slightly below all three moving averages, suggesting a potential downward trend in the short term.


**3. Technical Indicators & Expected Return:**

* **RSI (46.9):** Suggests the stock is approaching oversold territory, potentially indicating a bounce.
* **PPO (0.16):** A slightly positive PPO suggests some upward momentum, but it is weak.
* **20-day Relative Divergence Change (-6.2%):** Indicates a recent period of underperformance relative to the S&P 500.
* **Expected Return (0.0%):**  The provided expected return of 0% suggests that over the long term (2+ years) with consistent investment,  the stock is not expected to outperform the S&P 500.  This is consistent with the negative alpha values and underperformance noted above.  There is no information provided to explain if this figure is an estimate of alpha, a total return, or other metric.


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and revenue.

* **Revenue Growth:** Revenue shows generally upward trending growth, although there are minor fluctuations quarter to quarter.  There is no clear trend of acceleration or deceleration.
* **EPS Trends:** EPS figures fluctuate significantly, showing no consistent upward or downward trend.  The high of $2.15 in Q2 2024 is notable.
* **Comparison to Previous Quarters:**  There's no information provided to compare to expectations, so it is impossible to determine if there were any notable beats or misses.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue has shown overall growth, although the growth rate is not consistent. Profit margins have remained relatively stable and high.
* **Capital and Profitability:** Equity has increased over the period, but Return on Equity (ROE) is volatile, ranging from a negative value to over 12%. This variability indicates fluctuating profitability and possibly different accounting practices.

**6. News and Recent Issues:**

No information on recent earnings news, market outlook, or analyst opinions was provided.  This section cannot be completed.

**7. Overall Analysis:**

MRK has significantly underperformed the S&P 500 over the period analyzed, exhibiting negative alpha consistently.  While the current price is near oversold territory (RSI), this doesn't guarantee a rebound.  Recent earnings data shows some volatility in both EPS and revenue, without a clearly defined trend.   The 0% expected return against the S&P 500 further suggests that this stock is not expected to outperform the market.  More information, particularly around analyst opinions and future expectations, is necessary for a comprehensive assessment. The lack of recent news data prevents a full evaluation of current market sentiment and potential catalysts.  Based on the provided data alone, a cautious approach to investment is advised.


**8. Disclaimer:** This analysis is based solely on the limited data provided.  It is not financial advice and should not be used as the sole basis for investment decisions.  Independent research and consultation with a financial advisor are strongly recommended.
